Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta(®) in healthy subjects: A randomized, double‐blind trial

por Wynne, Chris, Schwabe, Christian, Vincent, Emmanuelle, Schueler, Armin, Ryding, Janka, Ullmann, Martin, Ghori, Vishal, Kanceva, Radmila, Stahl, Michael
Publicado 2020

Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models

por Pantoja, Kristyn, Lanke, Shankar, Munafo, Alain, Victor, Anja, Habermehl, Christina, Schueler, Armin, Venkatakrishnan, Karthik, Girard, Pascal, Goteti, Kosalaram
Publicado 2022

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

por Lebbé, Celeste, Dutriaux, Caroline, Lesimple, Thierry, Kruit, Willem, Kerger, Joseph, Thomas, Luc, Guillot, Bernard, de Braud, Filippo, Garbe, Claus, Grob, Jean-Jacques, Loquai, Carmen, Ferraresi, Virginia, Robert, Caroline, Vasey, Paul, Conry, Robert, Isaacs, Richard, Espinosa, Enrique, Schueler, Armin, Massimini, Giorgio, Dréno, Brigitte
Publicado 2020